4Gadducei A, Conte P, Cianci C, et al. Treatment options in patients with recurrent ovarian cancer [J]. Anticancer Res, 2001,21(5):3557- 3564.
5Strauss H G, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer[J]. Gynecol Oncol, 2007, 104(3):612- 616.
7Rose P G. Gemcitabine reverses platinum resistance in platinum- resistant ovarian and peritoneal carcinoma [J]. Int J Gynecol Cancer,2005,15(1) : 18-22.
6Uno K, nomma T, Satoh T, et at. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer[J]. Br J Cancer,2007,96(2) :290-295.
7Jandu N, Richardson M, Singh G, et al. Human ovarian cancer ascites fluid contain a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property[J], Int J Gynecol Cancer, 2006,16(4) : 1536 1544.
8方积乾.医学统计学与电脑实验[M].2版.上海:上海科学技术出版社,2007:327-331.
9Koh S C, Khalil R, Lim F K, et al. The association between fibrinogen, von Willebrand factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer [J]. Clin Appl Thrornb Hemost,2007,11(2):3-8.
10Diaz-Montes T P,Bristow R E.Secondary cytoreduction for patients with recurrent ovarian cancer[J].Curr Oncol Rep,2005,7(6):451-458.
10Li Y,Liu S,Wang C* Li K, et al. Novel biomarkers of 3-chloro-1,2-propanediol exposure by ultra performance liquidchromatography/mass spectrometry based metabonomic analysisof rat urine[J]. Chem Res Toxicol,2010,23(6) : 1012-1017.